Synapses are specialized structures that are critical for the transmission of information between neurons in the brain. Fine-tuning of the electrochemical activity at synapses underlies cognitive processes. In Alzheimer’s disease, memory loss coincides with synapse deterioration. The Tracy lab is investigating the molecular events that lead to synapse dysfunction and cognitive decline in Alzheimer’s disease and frontotemporal dementia. We think that synapses are particularly vulnerable to toxicity early in the progression of dementia before neurons begin to die. Tau, a microtubule-associated protein, accumulates in the brain and becomes toxic to neurons in Alzheimer’s disease and frontotemporal dementia. We are exploring how tau-mediated toxicity contributes to the emergence of synapse pathophysiology in these diseases. We are using mouse models and human induced pluripotent stem cell (iPSC)–derived neurons to dissect the mechanisms that trigger synapse and neuronal dysfunction during pathogenesis. Our long-term goal is to establish a foundation for new treatment strategies to restore synapse function and cognition at the early stages of disease progression before neurons are lost.
Why it matters
Millions of people are suffering from progressively debilitating dementia as they age, and the number of people diagnosed with Alzheimer’s disease is steadily rising. To advance our understanding of the mechanisms that promote cognitive decline in Alzheimer’s disease and frontotemporal dementia, it will be critical to discover the events that lead to synapse dysfunction and deterioration. This research may uncover new approaches for therapeutic intervention early in disease progression to promote the healthy aging of the brain.
It’s becoming obvious that intervening early in the disease process is essential in order to promote healthy aging of the brain. My lab is focused on discovering the early events that lead to neurodegeneration.
Tara Tracy, PhD
Dr. Tracy received her PhD in neuroscience from the University of California, Berkeley. She obtained postdoctoral training at the Gladstone Institute of Neurological Disease and University of California, San Francisco. Dr. Tracy was awarded a Ruth L. Kirschstein National Research Service Award from the National Institute on Aging and a BrightFocus Foundation Fellowship for her postdoctoral research to uncover mechanisms that promote memory loss in Alzheimer’s disease. She has received awards in recognition of her work from the Alzheimer’s Association and the Society for Neuroscience. Dr. Tracy’s research is currently supported by a Research Career Development Award from the National Institute on Aging.
H. C.Helen Cifuentes Administrative Lab Manager
Grant Kauwe, PhD Staff Scientist
Dr. Kauwe received his undergraduate degree in biology at the University of Hawaii at Manoa and his PhD in neuroscience at the University of California, Berkeley. He received postdoctoral training at the Buck Institute, where he focused on how diet regulates neuronal function. In the Tracy lab, he is investigating the dysregulation of plasticity at synapses underlying memory loss in neurodegenerative disease.
Ariana Myers Master's student
Ariana is currently pursuing an MS in Drug Discovery and Development from Drexel University College of Medicine. She brings a translational perspective together with her passion for neuroscience and biology of aging to her work uncovering the causes of synaptotoxicity in Alzheimer's and other neurodegenerative diseases. Prior to joining the Tracy Lab, Ariana spent five years working hands-on with seniors diagnosed with Alzheimer's disease.
- Tracy, T. E., Gan, L. (2018). Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease. Current Opinion of Neurobiology, 51, 134–138.
- Martinez-Losa, M. M.*, Tracy, T. E.*, Ma, K.*, Khan, A., Verret, L., Clemente, A., Cobos, I., Ho, K., Gan, L., Mucke, L., Alvarez-Dolado, M., Palop, J. J. (2018). Nav1.1-overexpressing interneuron transplants restore brain rhythms and cognition in a mouse model of Alzheimer’s disease. Neuron, 98, 75–89.
- Wang, C., Ward, M., Chen, R., Liu, K., Tracy, T. E., Chen, X., Xie, M., Sohn, P. D., Ludwig, C., Meyer-Franke, A., Ding, S., Gan, L. (2017). Scalable production of iPSC-derived human neurons to identify novel tau-lowering compounds by high-content screening. Stem Cell Reports, 9, 1221–1233.
- Tracy, T. E., Gan, L. (2017). Acetylated tau in Alzheimer’s disease: An instigator of the synaptic dysfunction underlying memory loss. BioEssays, 39, 4.
- Sohn, P. D.*, Tracy, T. E.*, Son, H. I., Zhou, Y., Leite, R., Miller, B., Seeley, W. W., Grinberg, L., Gan, L. (2016). Acetylated tau destabilizes the cytoskeleton in the axon initial segment and is mislocalized to the somatodendritic compartment. Molecular Neurodegeneration, 11, 47.
- Tracy, T. E., Sohn, P. D., Minami, S. S., Wang, C., Min, S. W., Zhou, Y., Li, Y., Le, D., Lo, I., Ponnusamy, R., Cong, X., Schilling, B., Ellerby, L., Huganir, R. L., Gan, L. (2016). Acetylated tau obstructs KIBRA-mediated signaling in synaptic plasticity and promotes tauopathy-related memory loss. Neuron, 90, 245–60.